Found in 2000, Zensun is a bio-tech pharmaceutical company well-versed in the demands of the international market with a high profit potential based on innovation. It is devoted to the research and development of new drugs through self-owned intellectual properties.
Zensun has long been focusing on the research of anti-tumor drugs and anti-heart failure drugs. Based on the innovative theory, Zensun has successfully developed two drugs: the Recombinant Human Neuregulin-1 injection, an anti-heart failure drug, and Recombinant Human ErbB3 fragment injection, a therapeutic vaccine against tumors, both have undergone clinical trial.
The Animal Research Center is a 400 sq. m. facility, encompassing specialized rooms for the breeding of rats, mice, rabbits and monkeys. At capacity the facility can house 7000 mice, 750 rats, 60 rabbits and 12 monkeys.
Cell Culture Facility consists of two experiment rooms and an observation room.
Zensun's Pilot Production Center is staffed by a team of experienced and entrepreneurial scientists, is equipped with state-of-the-art instrumentation and is maintained to provide the highest quality control. With a GLP standard production area of 200 sq. m., the Center consists of a 100,000th grade fermentation room, a purification room with a 10,000th grade area, and a 10,000th grade pharmacology preparation room, part of which is 100th grade.